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Abstract
Background: Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF) are Chronic Myeloproliferative
Neoplasms (MPN) characterized by clonal myeloproliferation/myeloaccumulation without cell maturation
impairment. The JAK2 V617F mutation and PRV1 gene overexpression may contribute to MPN physiopathology. We
hypothesized that deregulation of the apoptotic machinery may also play a role in the pathogenesis of ET and
PMF. In this study we evaluated the apoptosis-related gene and protein expression of BCL2 family members in
bone marrow CD34
+ hematopoietic stem cells (HSC) and peripheral blood leukocytes from ET and PMF patients.
We also tested whether the gene expression results were correlated with JAK2 V617F allele burden percentage,
PRV1 overexpression, and clinical and laboratory parameters.
Results: By real time PCR assay, we observed that A1, MCL1, BIK and BID, as well as A1, BCLW and BAK gene
expression were increased in ET and PMF CD34
+ cells respectively, while pro-apoptotic BAX and anti-apoptotic
BCL2 mRNA levels were found to be lower in ET and PMF CD34
+ cells respectively, in relation to controls. In
patients’ leukocytes, we detected an upregulation of anti-apoptotic genes A1, BCL2, BCL-XL and BCLW.I n
contrast, pro-apoptotic BID and BIMEL expression were downregulated in ET leukocytes. Increased BCL-XL protein
expression in PMF leukocytes and decreased BID protein expression in ET leukocytes were observed by Western
Blot. In ET leukocytes, we found a correlation between JAK2 V617F allele burden and BAX, BIK and BAD gene
expression and between A1, BAX and BIK and PRV1 gene expression. A negative correlation between PRV1 gene
expression and platelet count was observed, as well as a positive correlation between PRV1 gene expression
and splenomegaly.
Conclusions: Our results suggest the participation of intrinsic apoptosis pathway in the MPN physiopathology. In
addition, PRV1 and JAK2 V617F allele burden were linked to deregulation of the apoptotic machinery.
Keywords: Chronic Myeloproliferative Neoplasms, Apoptosis, JAK2 V617F allele burden, PRV1 , BCL2 family
members
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Essential Thrombocythemia (ET) and Primary Myelofi-
brosis (PMF) are disorders classified as Philadelphia
chromosome-negative Myeloproliferative Neoplasms
(MPN) [1]. ET is a clonal disease characterized by an
increase in the platelet count associated with bone mar-
row megakaryocyte hyperplasia. Thrombosis and hemor-
rhagic events are the main co-morbities in ET patients.
PMF is characterized by bone marrow fibrosis, as well
as peripheral blood findings such as anemia, leukoery-
throblastosis and the presence of dacryocytes in periph-
eral blood [2].
The JAK2 V617F mutation, which leads to constitutive
JAK2 activation, was shown to play an important role in
MPN pathogenesis, and is found in 95% of Polycythemia
Vera (PV) patients and in at least 50% of ET and PMF
patients [3]. Constitutive JAK2 activation triggers several
signaling pathways linked to cell survival and prolifera-
tion promoting myeloproliferation and resistance to cell
death [4-8]. Other mutations have recently been
described in ET and PMF patients, such as mutations in
JAK2 exon 12 and in the TET2, CBL, MPL and AXSL
genes [9-13]. Several studies suggest an association
between MPN clinical features and the JAK2 V617F
allele burden [14]. Although this knowledge and the
identification of these additional mutations greatly
enhanced our understanding of MPN physiopathology, a
complete understanding of the cellular and molecular
mechanisms involved is still lacking.
Another relevant molecular alteration described in
MPN patients is the overexpression of PRV1, a surface
receptor from hematopoietic cells associated with cell
proliferation [15] related to JAK/STAT and SRC kinase
pathways [16]. PRV1 overexpression was initially
described in PV patients and in some cases of ET, but
was not found elevated in other malignant hematologi-
cal diseases such as Chronic Myeloid Leukemia (CML)
[15,17,18]. Considering that PRV1 gene expression is
deregulated in MPN, it has been suggested that it may
be used as a molecular marker in the diagnosis of these
diseases [19]. Literature also supports the hypothesis
that PRV1 overexpression contributes to MPN physio-
pathology, considering that there are studies showing a
correlation between PRV1 expression and patients’ clini-
cal and laboratory features [15].
T h ea p o p t o s i sp r o c e s sm a yb et r i g g e r e db yt w om a j o r
pathways: the extrinsic or death-receptors pathway, and
the intrinsic or mitochondrial pathway. The intrinsic
apoptosis pathway or mitochondrial pathway is triggered
by several stimuli such as ultra violet radiation, growth
factor/cytokine deprivation, chemotherapeutic agents,
viral infection and other stress factors related to physical
and chemical injuries [20]. This pathway is mainly
regulated by BCL2 family members, classified as either
anti-apoptotic (BCL2, BCL-XL,B C L W ,M C L 1a n dA 1 )
or pro-apoptotic (BAX, BAK, BAD, BID, BIM, Bok, BIK,
BMF, BOO, BCL-XS, PUMA and NOXA) proteins [21].
The apoptotic process was found to be deregulated in
several hematopoietic neoplasms, leading to resistance
to therapy and progression of disease. Alterations in
apoptosis have been described in CML, Myelodysplastic
Syndrome (MDS), Acute Myeloid Leukemia (AML), PV,
ET and PMF [20,22-24].
In this study we investigated the potential association
between apoptosis deregulation, JAK2 mutation and
PRV1 overexpression in ET and PMF patients. We
focused on evaluating the expression of apoptosis-
related genes of the BCL2 family, JAK2 V617F allele
burden and PRV1 expression in ET and PMF in bone
marrow CD34
+ hematopoietic stem cells (HSC) and per-
ipheral blood leukocytes from ET and PMF patients.
The correlation between gene expression, JAK2 allele
burden, clinical and laboratory parameters and PRV1
expression were also assessed.
We observed a deregulation in the expression of most
of the studied genes in bone marrow CD34
+ cells and
peripheral leukocytes from ET and PMF patients in
comparison to controls. Furthermore, a correlation
between BAD, BAX and BIK expression and JAK2
V617F allele burden as well as between A1, BAX and
BIK and PRV1 expression was detected. A negative cor-
relation between PRV1 expression and platelet count
was also observed, as well as a positive correlation
between PRV1 expression and splenomegaly.
Subjects and methods
Patients and Controls
We studied bone marrow CD34
+ HSC and peripheral
blood leukocytes from 26 ET patients (5 male, 21
female, mean age: 60.2 years; range: 35-80y) and 12
PMF patients (9 male, 3 female, mean age: 61.7 years,
range: 41-80y), without treatment. The bone marrow
control group was composed of 23 bone marrow donors
from the Bone Marrow Transplantation Unit of the
Clinical Hospital - University of São Paulo at the
Ribeirão Preto School of Medicine, São Paulo, Brazil.
This group included 12 male and 11 female, with a
mean age of 35.9 years (range 14 -54y). We also col-
lected peripheral blood samples from 37 individuals
with similar age, skin color and gender (14 male, 23
female with mean age of 58.5 years, range 31-80y) for
leukocyte isolation. This research was approved by the
local ethics committees and the consent form was
signed by the patients and volunteer controls. It was not
possible to match the age and sex of bone marrow
donors because the local ethics committees only permit
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donors during the bone marrow transplantation cell col-
lection procedure.
JAK2 V617F allele burden detection, platelet count and
spleen size determination
Detection of the JAK2 V617F mutation and the allele
burden were determined as described in Tognon et al.,
2011 [24], by real time allelic discrimination PCR assay.
Platelets count from ET and PMF peripheral blood was
determined by the Abbott Cell Dyn 3500SL Hematology
Analyzer. Spleen size was determined by ultrasonogra-
phy. In order to correlate gene expression and spleno-
megaly, we used the increase in centimeters (cm) along
the longer dimension of the patients’ spleen, considering
as reference, a value of 12 cm.
Cell Isolation, RNA extraction and cDNA synthesis
Cell isolation, RNA extraction and cDNA synthesis
were performed as described in Tognon et al., 2011
[24]. Briefly, bone marrow CD34
+ HSC were separated
using the Ficoll-Hypaque protocol followed by Miltenyi
CD34 isolation kit MidiMacs CD34
+ Isolation Kit
(MACS; Miltenyi Biotec, Bergisch Gladbach, Germany)
and peripheral leukocytes were obtained by the Haes-
Steril method. Total RNA from CD34
+ HSC and leu-
kocytes was extracted according to the Trizol™ (Invi-
trogen Life Technologies, CarlsBAD, California, USA)
method. One microgram of RNA was used to synthe-
size cDNA using the High Capacity™ Kit from
Applied Biosystems Life Technologies (Foster City,
California, USA).
Quantification of apoptosis-related gene and PRV1
expression
The expression of anti-apoptotic genes A1, MCL1,
BCL2, BCL-XL and BCLW and pro-apoptotic genes
BAD, BAX, BAK, BID, BIK and BIMEL was evaluated by
real time PCR in duplicate. For gene expression quanti-
fication we used the SYBR Green PCR Master Mix Kit
(Applied Biosystems) and specific oligonucleotides (Invi-
trogen Life Technologies) (Table 1) on the 7500 Real
Time PCR System (Applied Biosystems Life Technol-
ogy). The results were normalized by the geometric
mean of the beta-actin and the GAPDH housekeeping
genes expression and represented by 2
-ΔΔCt as described
by Tognon et al., 2011 [24].
The PRV1 gene was quantified by the TaqMan PCR
Master Mix kit using TaqMan
® Gene Expression Assay
(PRV1 - Hs00360669_m1; GAPDH -Hs99999905_m1)
on Mastercycler
® ep Realplex (Eppendorf AG, Hamburg,
Germany). For this gene, GAPDH was used as house-
keeping gene.
Western Blot
One million leukocytes were lysated in 100 uL of sample
buffer (5% mercaptoethanol, 4% sodium dodecyl sulfate
- SDS, 20% glycerol and 100 mM Tris-HCl-pH 6.8),
boiled at 100°C for 5 minutes and kept at -20°C until
the Western-Blot analysis was performed. Twenty-five
ml of patient and controls’ lysate were loaded in polya-
crilamide gel, the proteins were separated on 15% SDS-
PAGE and transferred onto polyvinylidene difluoride
(PVDF) membrane (Amersham, GE Healthcare Life
Science). The membranes were incubated with the pri-
mary antibody anti-BCL-XL (1:200 dilution, H-62,
SC7195, Santa Cruz Biotechnology
®) or anti-BID (1:500
dilution, # 611528, BD Pharmingen) diluted in TBS-
Tween (20 mM Tris, 137 mM NaCl, 0.01% Tween-20)
with 5% non-fat milk for 16 hours. As a control for
sample loading, the blot was probed with anti-g-tubulin
(1:2000 dilution, T3320, Sigma-Aldrich). Horseradish
peroxidase (HRP) conjugated secondary antibodies and
ECL Plus
® (Amersham, GE Healthcare Life Science)
were used for protein expression detection. Protein
expression was measured by densitometry analysis per-
formed by ImageQuant TL (Image Analysis Software,
2005, Amersham). To express the proteins densitometry
results, firstly we calculated the ratio between protein
test IDV (Integrated density value) and tubulin IDV, and
Table 1 Real time PCR primer sequences
Gene Primer Sequence
A1 F: GGC TGG CTC AGG ACT ATC
R: CCA GTT AAT GAT GCC GTC
MCL1 F: AGA AAG CTG CAT CGA ACC AT
R: CC AGC TCC TAC TCC AGC AAC
BCL2 F: ACG AGT GGG ATG CGG GAG ATG TG
R: GCG GTA GCG GCG GGA GAA GTC
BCLW F: AGT TCG AGA CCC GCT TCC
R: CCC GTC CCC GTA TAG AGC
BCL-XL F: CTG AAT CGG AGA TGG AGA CC
R: TGG GAT GTC AGG TCA CTG AA
BID F: GCT TCC AGT GTA GAC GGA GC
R: GTG CAG ATT CAT GTG TGG ATG
BIK F: TCT GCA ATT GTC ACC GGT TA
R: TTG AGC ACA CCT GCT CCT C
BIMEL F: GCC CCT ACC TCC CTA CAG AC
R: AAG ATG AAA AGC GGG GAT CT
BAD F: CCG AGT GAG CAG GAA GAC TC
R: GGT AGG AGC TGT GGC GAC T
BAK F: TCT GGC CCT ACA CGT CTA CC
R: ACA AAC TGG CCC AAC AGA AC
BAX F: CCC TTT TGC TTC AGG GTT TC
R: TCT TCT TCC AGA TGG TGA GTG
b-actin F: GCC CTG AGG CAC TCT TCC A
R: CCA GGG CAG TGA TCT CCT TCT
GAPDH F: GCCTCAAGATCATCAGCAATGC
R: CATGGACTGTGGTCATGAGTCCT
F: Forward Primer, R: Reverse Primer
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patient and controls (IDV of patients protein expression
divided by controls protein expression).
Statistical analysis
The Mann-Whitney test (t-test, one-tailed) was used to
compare the values of gene expression among the studied
groups. The correlations between apoptosis-related gene
expression, JAK2 allele burden and PRV1 gene expres-
sion were carried out by Spearman tests using Prisma 5.0
Software. A p value < 0.05 was taken as significant.
Results
Gene expression of apoptosis-related BCL2 family
members is deregulated in ET and PMF patients
Gene expression analysis in CD34
+ HSC from ET patients
showed an increased expression of anti-apoptotic genes
A1 and MCL1 and of pro-apoptotic genes BID and BIK
(median = 39.25, 2.07, 5.69 and 2.99, respectively) in com-
parison to controls (0.986, 0.431, 1.15 and 1.36, respec-
tively) (p < 0.0001, p = 0.0349, p = 0.0128 and p = 0.0279,
respectively) (Figure 1A-D). The mRNA level of the pro-
apoptotic gene BAX was found to be lower (0.19) in
patients than controls (5.08) (p = 0.0319) (Figure 1E).
In PMF CD34
+ HSC the anti-apoptotic genes A1,
BCLW and pro-apoptotic BAK expression were signifi-
cantly increased (21.11, 1.55 and 11.67, respectively)
compared to controls (0.99, 1.01 and 1.67, respectively)
(p = 0.0002, p = 0.0125 and p = 0.0460, respectively)
(Figure 1A, F and 1G). BCL2 mRNA levels were down-
regulated in these cells (0.18) in comparison to controls
(1.99) (p = 0.0086) (Figure 1H).
In ET patients’ leukocytes we found an overexpres-
sion of the anti-apoptotic genes A1, BCL2, BCL-XL and
BCLW (16.10, 2.21, 2.71 and 2.21, respectively) when
compared with controls (0.49, 0.88, 0.80 and 1.06,
Figure 1 Gene expression in Control, ET and PMF CD34
+ HSC. (A) anti-apoptotic gene A1 was increased in ET and PMF compared to
control; (B) anti-apoptotic gene MCL1 was increased in ET compared to control; (C) pro-apoptotic gene BID was increased in ET compared to
control; (D) pro-apoptotic gene BIK was increased in ET compared to control; (E) pro-apoptotic gene BAX was decreased in ET compared to
control; (F) anti-apoptotic gene BCLW was increased in PMF compared to control; (G) pro-apoptotic gene BAK was increased in ET compared to
control; (H) anti-apoptotic gene BCL2 was decreased in PMF compared to control. The significant “p values” are shown in the figure. Otherwise, p
> 0.05. The horizontal bars show the median 2
-ΔΔCt for each group.
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= 0.0342, respectively) (Figure 2A-D). The expression
of pro-apoptotic genes BID and BIMEL was lower in
ET leukocytes (0.62, 0.53) than in controls (1.43, 0.86)
(p = 0.0004, p = 0.0116) (Figure 2E, F).
In PMF leukocytes, BCL2, BCL-XL and BCLW expression
were elevated (9.17, 16.10, 27.86, respectively) compared to
controls (0.88, 0.80 and 1.07, respectively) (p = 0.0291, p <
0.0001 and p = 0.0007, respectively) (Figure 2B, C and 2D).
Pro-apoptotic BAD expression was found to be increased
in ET and PMF leukocytes (3.92, 5.18) compared to con-
trols (0.63) (p = 0.0130, p = 0.0276) (data not shown).
There were no differences when we compared BCL-XL
,B A Dand BIMEL expression between CD34
+ cells from
ET and PMF patients and controls, and this was also
the case for M C L 1 ,B I D ,B I Kand BAX expression in
leukocytes (p > 0.05). Furthermore, between ET and
PMF leukocytes we only found a significant difference
in BCLW and BCL-XL expression (p = 0.0145, p =
0.0033) (Figure 2C and 2D).
BCL-XL and BID protein levels were different between
controls and PMF and ET patients
We detected an elevated level of anti-apoptotic BCL-XL
in PMF leukocytes and a decreased expression of pro-
apoptotic BID protein in ET leukocytes in comparison
to control subjects (Figure 3A and 3B). Densitometry
quantification by Integrated Density Value (IDV)
showed that BCL-XL protein level is 2.4 times higher in
PMF leukocytes than in controls, and BID protein in ET
Figure 2 Gene expression in Control, ET and PMF leukocytes. (A) anti-apoptotic gene A1 was increased in ET compared to control; (B) anti-
apoptotic gene BCL2 was increased in ET and PMF compared to control; (C) anti-apoptotic gene BCL-XL was increased in ET and PMF compared
to control and also significantly different between ET and PMF; (D) anti-apoptotic gene BCLW was increased in ET and PMF compared to control
and also significantly different between ET and PMF; (E) pro-apoptotic gene BID was decreased in ET compared to control; (F) pro-apoptotic
gene BIMEL was decreased in ET compared to control. The significant “p values” are shown in the figure. Otherwise, p > 0.05. The horizontal bars
show the median 2
-ΔΔCt for each group.
Figure 3 Protein expression in Control, ET and PMF leukocytes.
(A) anti-apoptotic BCL-XL showed higher expression in PMF leukocyte
than in controls (fold change: 2.4); (B) pro-apoptotic BID showed lower
expression in ET leukocyte than in controls (fold change: 0.64). Tubulin
was probed as loading control and densitometry was used to confirm
the fold change in the protein expression.
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expression in controls.
JAK2 V617F allele burden is correlated with BAD, BAX
and BIK expression in ET patients’ leukocytes
In JAK2 V617F-positive ET patients we detected lower
levels of pro-apoptotic BAX, BIK and BAD expression
(median: 0.26, 0.45 and 1.86, respectively) in leukocytes
compared to JAK2 V617F-negative ET patients (1.59,
2.96 and 11.10, respectively) (p = 0.0189, p = 0.0309 and
p = 0.0055, respectively) (Figure 4A-C). In addition,
BAX, BIK and BAD expression were negatively corre-
lated with JAK2 V617F allele burden (BAX: r = -0.4522;
p = 0.0102; BIK: r = -0.4067, p = 0.0196; BAD:r=
-0.5966, p = 0.0006) in ET (Figure 4D-F).
PRV1 overexpression is correlated with A1, BIK and BAX
gene expression, JAK2 V617F mutation, platelet count
and splenomegaly
We observed that PRV1 was overexpressed in ET (3.04)
and PMF (5.12) leukocytes in comparison to controls
(0.93) (p = 0.0011 and p = 0.0009) (Figure 5A). In ET leu-
kocytes we also found that PRV1 expression was positively
correlated with A1 expression (r = 0.3409, p = 0.0442),
and negatively correlated with expression of BAX (r=-
0.3791, p = 0.0281) and BIK (r=-0.5009, p = 0.0046)
(Figure 5B-D). Moreover, PRV1 expression was positively
correlated with BCLW (r = 0.6503, p = 0.0110) expression
in PMF patients’ leukocytes (Figure 5E).
We detected a positive correlation between PRV1
expression and JAK2 V617F mutation allele burden in ET
and PMF patients and this result corroborates the litera-
ture concerning the association between PRV1 and JAK2
V617F described in murine myeloid cells [25] and PV
patients [26]. Leukocytes from ET patients harboring the
JAK2 V617F mutation showed higher expression of PRV1
(median = 4.88) in comparison to those negative for the
JAK2 V617F mutation (1.91) (p = 0.0074) (Figure 6A) and,
consequently, a positive correlation between PRV1 expres-
sion and JAK2 V617F allele burden was observed in ET
patient leukocytes (r = 0.4785; p = 0.0067) (Figure 6B).
Furthermore, PRV1 expression was negatively corre-
lated with platelet count in ET (r=-0.3799, p = 0.0278)
(Figure 7A) and PMF patients (r=-0.6713, p = 0.0084)
(Figure 7B), and PRV1 expression in PMF leukocytes
showed a positive correlation with the increase of the
spleen size in centimeters (splenomegaly) (r = 0.6150,
p = 0.0220) (Figure 7C).
Discussion
Our results indicate a deregulated expression of genes
related to the intrinsic apoptosis pathway in CD34
+
HSC and peripheral leukocytes from ET and PMF
patients.
Our hypothesis was that higher expression levels of
anti-apoptotic genes may contribute to the myeloaccu-
mulation in ET and PMF. In support of this notion, in
this study we found increased expression of A1, MCL1,
Figure 4 Apoptosis-related gene expression versus JAK2 V617F mutation. (A, B and C) pro-apoptotic genes BAX, BIK and BAD showed
lower expression in ET JAK2 V617F positive patients compared to negative patients; (D, E and F) BAX, BIK and BAD expression in ET leukocytes
also negatively correlated with the patients’ JAK2 V617F allele burden. The significant “p values” and the “r value” for correlations are shown in
the figure. The horizontal bars show the median 2
-ΔΔCt for each group.
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pared to controls. Importantly, as previously described
by our group, the cells from MPN patients are resistant
to apoptosis induced by different drugs (actinomycin D,
teniposide, etoposide, cytarabin, and staurosporin) [24].
These observations, and our findings in the present
investigation, support our hypothesis that deregulated
expression of apoptosis-related genes is linked to mye-
loaccumulation and pathogenesis in ET and PMF.
The BCL2 family proteins have a central role in the
process of apoptosis control. The A1, BCL2, BCLW,
BCL-XL and MCL1 BCL2-family members encode anti-
a p o p t o t i cm o l e c u l e s ,w h i l eB A D ,B A X ,B A K ,B I D ,B I K ,
BOK, BOO, PUMA, NOXA and BIMEL encode pro-
apoptotic molecules, all of them involved in the mito-
chondrial apoptosis pathway [21].
A1 (bfl1) expression is detected in several tissues such
as hematopoietic and endothelial cells [27]. A1 gene
transcription is dependent on the NF-kB pathway and
its overexpression has been reported in Chronic Lym-
phocytic Leukemia (CLL), particularly in CLL patients
who do not respond to therapy [27].
BCL2 is an oncogene, which was first identified in
Non-Hodgkin lymphoma B-cells and this gene is a pivo-
tal molecule in the mitochondrial apoptosis pathway.
Castro et al. (2005) described in the American Society
Figure 5 PRV1 gene expression in Control, ET and PMF leukocytes and PRV1 expression versus gene expression.( A )PRV1 expression
was significantly elevated in ET and PMF leukocytes; (B) anti-apoptotic gene A1 showed positive correlation with PRV1 expression in ET
leukocytes; (C and D) pro-apoptotic genes BAX and BIK showed negative correlation with PRV1 expression in ET leukocytes; (E) anti-apoptotic
gene BCLW showed positive correlation with PRV1 expression in PMF leukocytes. The significant “p values” are shown in the figure. Otherwise, p
> 0.05. The horizontal bars show the median 2
-ΔΔCt for each group.
Figure 6 PRV1 expression versus JAK2 V617F mutation.( A )PRV1 expression was higher in ET JAK2 V617F positive patients than in JAK2
V617F negative patients; (B) a positive correlation between PRV1 expression in ET leukocytes and JAK2 V617F allele burden percentage was
detected. The significant “p values” and the “r value” for correlations are shown in the figure.
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sion and an increase in BCL-XL, BCLW, A1, MCL1 and
cflip expression in CML and they also demonstrated
that this profile of expression was correlated with CML
progression. Furthermore, many publications have
shown that in neoplasms such as breast or stomach can-
cer, high levels of BCL2 proteins were associated with a
worse prognosis [29].
Deregulation of MCL1expression was described in
hepatocellular carcinoma [30] and in multiple myeloma
[31]. Furthermore, the expression of this gene was also
found to be correlated with prognosis in multiple mye-
loma [31]. Such deregulated expression was also verified
in bone marrow blasts from patients with MDS [22].
Del Poeta et al. reported increased levels of BCL2, BCL-
XL and MCL1 expression in AML [23] and Aichberger
et al. showed that MCL1 is a BCR-ABL target gene in
CML [32].
Among the pro-apoptotic proteins of the BCL2 family,
BAX has a crucial role in apoptosis and the lack of BAX
leads to apoptosis impairment and facilitates the develop-
ment of B-cell lymphoma by c-Myc stimulation [33].
Regarding MPN pathophysiology, Zhang et al. [34]
demonstrated that BCL-XL is down-regulated early dur-
ing in vitro differentiation of megakaryocytes from ET
patients and this might reflect an early entry of megakar-
yocytes into a degenerating mature stage [34]. There is
little data in the literature regarding apoptosis deregula-
tion in PMF. On one hand, Mesa et al. (2006) showed
that the levels of the anti-apoptotic and pro-apoptotic
BAX, BAK, BIM and Bmf were not different between
P M Fa n dc o n t r o l s[ 3 5 ] .O nt h eo t h e rh a n d ,i tw a s
demonstrated that JAK2 inhibition in a cellular model of
MPN (JAK2 V617F positive cell lineage) triggers BIM
activation and leads to enhanced sequestration of MCL1,
furthermore, BCL-XL and MCL1 depletion by RNAi was
sufficient to compromise JAK2 V617F mutant cell viabi-
lity and sensitized the cells to JAK2 inhibition, indicating
an association between these apoptosis-related molecules
and the aberrant JAK2 signaling in these cells [36].
Figure 7 Correlation of PRV1 gene expression with platelet count (PLT) and splenomegaly. PRV1 expression in ET (A) and PMF (B)
leukocytes showed negative correlation with platelets (PLT); (C) PRV1 expression in PMF leukocytes showed positive correlation with the increase
in centimeters of the spleen length (splenomegaly) determined by ultrasonography (reference value: 12 cm). The significant “p values” and the
“r” value for correlations are shown in the figure.
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interact with each other to control the intrinsic apop-
tosis pathway [37]. The balance among the activities of
these proteins is very important to tightly control the
apoptosis process [38]. The MPN patients enrolled in
this study showed overexpression of several anti-
apoptotic genes such as A1 and MCL1 but also overex-
pression of some pro-apoptotic genes such as BIK, BID
and BAK in CD34
+ cells. Furthermore, in CD34
+ cells
we observed a downregulation of BAX and BID,a n d
BIMEL levels were found reduced in ET leukocytes.
Therefore, we postulate that the balance among these
BCL2 family members is disrupted, and may contribute
to the myeloaccumulation in these patients due to the
increase in cell survival.
In addition, we found that mRNA levels of pro-apopto-
tic BAX, BAD and BIK mRNAs were lower in JAK2
V617F-positive patients than in those negative, and also
presented a negative correlation with the JAK2 V617F
allele burden. Some reviews published in the literature
have already pointed out and discussed the relationship
between constitutively activated JAK2/STAT signaling
and deregulation of apoptosis-related genes in CML and
human tumor cell lines [39,40].
Moreover, we analyzed PRV1 mRNA expression and
the correlation with JAK2 V617F mutation, and with
clinical laboratorial data in leukocytes from control, ET
and PMF patients. PRV1 is a hematopoietic cell surface
receptor that has been shown to transduce intracellular
signals leading to proliferation, involving JAK2 and Src
kinases [16]. PRV1 is overexpressed in MPN patients
[15,19,41,42] and seems to be associated with PV disease
phenotype characterized by high erythrocyte and low pla-
telet counts [15]. These studies also described a correla-
tion between PRV1 expression and the JAK2 V617F allele
burden, as well as between PRV1 overexpression and ele-
vated JAK2 tyrosine kinase activity [15,19,25,41,42].
In our results we detected a correlation between PRV1
overexpression and the anti-apoptotic genes A1 and
BCLW, and the pro-apoptotic genes BAX and BIK expres-
sion. We also found a differential expression of PRV1
according to JAK2 V617F status and a correlation between
PRV1 expression and platelet count in ET and PMF
patients, as well as splenomegaly. Thus, our results suggest
a link between PRV1 and intrinsic apoptosis pathway regu-
lation and are in good agreement with previous reports
about the association of the JAK2 V617F mutation with
deregulation of apoptosis and disease phenotype [25].
An illustrative overview of the gene expression results in
CD34
+ HSC and leukocytes from ET and PMF is shown in
Figure 8. This figure highlights the complexity of the apop-
tosis network in MPN patients. The analysis of the interac-
tion of genes involved in the apoptotic machinery described
here implies that apoptosis is deregulated and impaired in
MPN patients since the majority of anti-apoptotic genes
assessed are overexpressed, while concomitantly, some pro-
apoptotic genes appear to be downregulated.
These observations are in line with previous results
described by our group in Tognon et al. (2011) [24],
which demonstrated that mononuclear cells from MPN
patients are resistant to apoptosis, considering that
patients’ cells stimulated by numerous apoptotic indu-
cers, such as actinomycin and cytarabin, showed less
Annexin-V FITC staining compared to controls [24].
Therefore, deregulation of the intrinsic apoptosis path-
way might contribute to ET and PMF physiopathology
and myeloaccumulation.
MPN do not yet have a curative therapy so it is parti-
cularly relevant to consider the possibility of designing
new drugs targeting apoptosis pathway. In this context,
Zivny et al. (2010) reviewed this subject emphasizing the
importance of developing new and more effective target
cancer therapies with the potential of inhibiting the
anti-apoptotic BCL2 family members or enhancing pro-
Figure 8 Overview of the BCL2 family gene expression results:( A )i nC D 3 4
+ HSC and (B) leukocytes from patients with ET (continuous
arrows) and PMF (stippled arrows).
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might impair evasion of tumor cell to apoptosis pro-
cesses or might sensitize cells to apoptosis. Taken
together our results suggest that ET and PMF treatment
could not be restrict to JAK2 inhibitors, considering
that there are other molecular mechanisms involved in
MPN pathogenesis, in addition to JAK2 mutation.
Maybe in the future, JAK2 inhibitor treatment must be
associated with new target therapies, such as anti-apop-
totic BCL2 family members’ inhibitors or pro-apoptotic
enhancers, for better patients ‘ response to therapy.
Conclusion
CD34
+ HSC and leukocytes from ET and PMF patients
displayed a deregulation in expression levels of BCL2
family members, which are correlated with JAK2 V617F
mutation and PRV1 mRNA levels. Our findings suggest
that these alterations may contribute to increased resis-
tance to apoptosis and to myeloaccumulation in ET and
PMF patients.
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